Roles at http://pharmaceuticalintelligence.com
Editor, Nanotechnology for Drug Delivery
Research Category OWNER:
Nanotechnology for Drug Delivery – Investigator Initiated New Research Category
Expert, Author, Writer:
- CANCER BIOLOGY & Innovations in Cancer Therapy
- Cell Biology, Signaling & Cell Circuits
Tilda Barliya, PhD
tildabarliya@gmail.com
Personal Bio
Specialties: Oncology, Cell biology, Ophthalmology and Nanotechnology.
I am a research scientist at the Department of Ophthalmology at the Rabin Medical Center.
- I am a highly skilled cancer cell biologist with strong background and interest in nanotechnology for drug delivery. I completed my first Post-doctoral fellowship at Weill Cornell Medical Center in NYU exploring the preventative effects of different chemotherapeutic drugs on breast cancer progression. Thereafter I conducted a second post-doc at UNC in field of nanotechnology exploring new drug delivery platforms and performed as an active editor and author in several scientific blogs. Few years ago, I joined the ophthalmology research team at the Rabin Medical Center exploring new application of nanotechnology in eye diseases as well as understanding the underlying cause of different retinal diseases.
- I bring a wide-spectrum of expertise in multidisciplinary field of nanotechnology oncology as well as ophthalmology.
Professional in the fields of biotechnology, nanotechnology and medical devices. PhD in tumor and vascular biology from Sackler School of Medicine, Tel-Aviv University, with 10 years of experience in Cancer research. Explored and developed the antiangiogenic properties of Hypericin. Drug entered Phase I clinical trials for the treatment of brain tumors.
Expertise in the following fields:
- Tumor cell biology (In vivo and In vitro: WB, IF, ELISA, IP, RT-PCR,SEM)
- Vascular biology
- Imaging tools: Tumor imaging in vivo; live tumor visualization ,microscopy
- Nanoparticles fabrication (PLGA, PEG)
- Rational drug design
- Drug encapsulation in nanoparticles and analysis of drug release profile (HPLC).
Educational and Professional History
Rabin Medical Center-Beilinson Campus, Israel present
Research Project Manager: supervised by Prof. Dov Weinberger, head of the Ophthalmology department.
- Developing new applications of surgical sealants for different eye diseases.
- Developing ferro-based nano vehicles for eye surgeries.
- Evaluating the feasibility of magnetic-remote control over ferro-based nano vehicles for eye surgeries.
- Evaluating the feasibility of a new medical device for IOP
UNC, Chapel Hill, NC, USA 2010-Early 2012
Post Doctoral Fellow: Supervised by Prof. Joseph DeSimone.
Research Subject- Study and evaluate Chemo-loaded NPs of different size and shape for cancer models.
- Nanoparticle fabrication, drug encapsulation and encapsulation analysis
- In vitro release studies of encapsulated drugs
- In vivo pharmacokinetics (PK) studies
- In vivo Imaging – Found a novel approach for tumor imaging using the PLGA-dye polymer
- An academic lab using a business platform with the appropriate Q-meetings and internal lab reports.
- Writing SOP for and conducted research under GMP conditions.
Weill Cornell Medical College, NYC, USA 2007-2010
Post Doctoral Fellow: Supervised by Dr. Meena Katdare
Research Subject- Study mutagens and carcinogens associated with mammary tumorgenesis pathways.
- Susan G. Kolmen for the cure “Scholar-In-Training Award” for the AAC Frontier in Cancer Prevention Research Conference (2008)
- Supervised a group of PhD students, surgery residents and pre-Med students
- Expert in Tumor cell biology and tissue culture
- Tumor-animal studies and drug administration
Tel-Aviv University, Tel-Aviv, Israel 2003-2007
PhD in Medical Science/ Cell Biology: Supervised by Dr. Gad Lavie
Department of Cell Biology, Sackler School of Medicine
PhD thesis: “The mechanism of inhibition of angiogenesis by Hypericin”
- Found the antiangiogenic properties of Hypericin. Hypericin was re-patented by HyBiopharma and enter phase I clinical trials for glioblastoma. HyBiopharma www.hybiopharma.com
- A research assistant for a project on Multiple Sclerosis (MS) in the Sheba Medica Center, Tel – Hashomer, Ramat Gan.
- First place awarder at the Sheba Medical Center Research day (2004)
- Travel fellowship by Michaelson Club Symposium for Eye Research (2007)
- Supervised and guided master students in their projects.
Tel-Aviv University, Tel-Aviv, Israel 2000-2002
M.Sc in Medical Science/ Cell Biology: Supervised by Dr. Lavie
Department of Cell Biology, Sackler School of Medicine.
- Graduated with honor
- Research assistant for a project on Multiple Sclerosis (MS) in the Sheba Medical Center, Tel – Hashomer, Ramat Gan.
- Volunteered as a tutor for students with learning difficulties.
Tel -Aviv University, Tel-Aviv, Israel 1998-2000
B.Sc in Life Science
- Volunteered as a tutor for students with learning difficulties.
Professional work experience
2000- 2007 – Sheba Medical Center- Tel Hashomer
Acquired knowledge while being a research assistant in a clinical trial for Multiple Sclerosis patients in the Sheba Medical Center (Israel). This experiment included producing T-cell vaccinations, characterizing them on their TCR vβ and gene profiles.
- In vitro; T cell receptor sequencing
Awards and Scholarships
2004 – First place awarde at the Sheba Medical Center Research day
2007 – Travel fellowship by Michaelson Club Symposium for Eye Research
2008 – Susan G. Kolmen for the cure “Scholar-In-Training Award” for the AACR Frontier in Cancer Prevention Research Conference
Workshops
2004 – Tel Aviv University Cancer Research Center, Cefar Blum, Israel
2004 – Sheba Medical Center Research day
2005 – Michaelson Club Symposium for Eye Research, Belgium
2006 – Israeli Eye Research, Neve Ilan, Israel
2007 – Israeli Eye Research, Neve Ilan, Israel
2007 – Tel Aviv University Cancer Research Center, Israel
2007 – Michaelson Club Symposium for Eye Research, Baltimore USA.
2008 – AACR Frontiers in Cancer Prevention Research Conference, Washington DC,
2010 – 101 annual AACR meeting, Washington DC, USA
Publications
Barliya T., Mandel M., Livnat T., Weinberger D and Lavie G. “Degradation of HIF-1alpha Under Hypoxia Combined with Induction of Hsp90 Polyunbiquitination in Cancer Cells by Hypericin; a Unique Cancer Therapy”. PLoS ONE, 6(9) Sep 19, 2011.
Barliya T and Katdare M. “Preventive efficacy of curcumin on ENU-induced carcinogenic transformation of ApcMin/+ mammary epithelial (MinMG) cells established from ApcMin/+ mouse”. 101 Annual AACR meeting will be held in April 2010. Abstract.
Brooks R*., Barliya T.,*, Wynne N and Katdare M. “APC gene mutation and its role in breast carcinogenesis: Curcumin as a chemopreventive phytochemical”. J Am Coll Sur October 2009. Abstract. *co-authors
Barliya T., Gall-Troselj K., Crawford C. and Katdare M. “Curcumin downregulates IL-8 in DCIS breast cancer cells; correlation between tumorgenecity and inflammation”. 7th Annual AACR conference on Frontiers in Cancer Prevention Research, Nov. 2008; p38 (A34). Abstract
Mandel M, Achiron A, Tuller T, Barliya T, Rechavi G, Amariglio N, Loewenthal R, Lavie G. Clone clusters in autoreactive CD4 T-cell lines from probable multiple sclerosis patients form disease-characteristic signatures. Immunology 2009 Oct;128(2):287-300.
Lavie G, Barliya T et al. Competitive quenching”: a mechanism by which perihydroxylated perylenequinone photosensitizers can prevent adverse phototoxic damage caused by verteporfin during photodynamic therapy. Photochem Photobiol. 2007 Sep-Oct;83(5):1270-7.
Hazan Z, et al.Effective prevention of microbial biofilm formation on medical devices by low-energy surface acoustic waves. Antimicrob Agents Chemother. 2006 Dec;50(12):4144-52. Epub 2006 Aug 28.
Lavie G. et al. Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis. 2005;8(1):35-42.
Weinberger D. et al. Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT. Curr Eye Res. 2005;30(4): 269-277.
Achiron A.et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol. 2004;113(2):155-160.
Languages
Hebrew – native
English – fluent
French – Basic
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
PUT IT IN CONTEXT OF CANCER CELL MOVEMENT
The contraction of skeletal muscle is triggered by nerve impulses, which stimulate the release of Ca2+ from the sarcoplasmic reticuluma specialized network of internal membranes, similar to the endoplasmic reticulum, that stores high concentrations of Ca2+ ions. The release of Ca2+ from the sarcoplasmic reticulum increases the concentration of Ca2+ in the cytosol from approximately 10-7 to 10-5 M. The increased Ca2+ concentration signals muscle contraction via the action of two accessory proteins bound to the actin filaments: tropomyosin and troponin (Figure 11.25). Tropomyosin is a fibrous protein that binds lengthwise along the groove of actin filaments. In striated muscle, each tropomyosin molecule is bound to troponin, which is a complex of three polypeptides: troponin C (Ca2+-binding), troponin I (inhibitory), and troponin T (tropomyosin-binding). When the concentration of Ca2+ is low, the complex of the troponins with tropomyosin blocks the interaction of actin and myosin, so the muscle does not contract. At high concentrations, Ca2+ binding to troponin C shifts the position of the complex, relieving this inhibition and allowing contraction to proceed.
Figure 11.25
Association of tropomyosin and troponins with actin filaments. (A) Tropomyosin binds lengthwise along actin filaments and, in striated muscle, is associated with a complex of three troponins: troponin I (TnI), troponin C (TnC), and troponin T (TnT). In (more ) Contractile Assemblies of Actin and Myosin in Nonmuscle Cells
Contractile assemblies of actin and myosin, resembling small-scale versions of muscle fibers, are present also in nonmuscle cells. As in muscle, the actin filaments in these contractile assemblies are interdigitated with bipolar filaments of myosin II, consisting of 15 to 20 myosin II molecules, which produce contraction by sliding the actin filaments relative to one another (Figure 11.26). The actin filaments in contractile bundles in nonmuscle cells are also associated with tropomyosin, which facilitates their interaction with myosin II, probably by competing with filamin for binding sites on actin.
Figure 11.26
Contractile assemblies in nonmuscle cells. Bipolar filaments of myosin II produce contraction by sliding actin filaments in opposite directions. Two examples of contractile assemblies in nonmuscle cells, stress fibers and adhesion belts, were discussed earlier with respect to attachment of the actin cytoskeleton to regions of cell-substrate and cell-cell contacts (see Figures 11.13 and 11.14). The contraction of stress fibers produces tension across the cell, allowing the cell to pull on a substrate (e.g., the extracellular matrix) to which it is anchored. The contraction of adhesion belts alters the shape of epithelial cell sheets: a process that is particularly important during embryonic development, when sheets of epithelial cells fold into structures such as tubes.
The most dramatic example of actin-myosin contraction in nonmuscle cells, however, is provided by cytokinesisthe division of a cell into two following mitosis (Figure 11.27). Toward the end of mitosis in animal cells, a contractile ring consisting of actin filaments and myosin II assembles just underneath the plasma membrane. Its contraction pulls the plasma membrane progressively inward, constricting the center of the cell and pinching it in two. Interestingly, the thickness of the contractile ring remains constant as it contracts, implying that actin filaments disassemble as contraction proceeds. The ring then disperses completely following cell division.
Figure 11.27
Cytokinesis. Following completion of mitosis (nuclear division), a contractile ring consisting of actin filaments and myosin II divides the cell in two.
http://www.ncbi.nlm.nih.gov/books/NBK9961/
This is good. I don’t recall seeing it in the original comment. I am very aware of the actin myosin troponin connection in heart and in skeletal muscle, and I did know about the nonmuscle work. I won’t deal with it now, and I have been working with Aviral now online for 2 hours.
I have had a considerable background from way back in atomic orbital theory, physical chemistry, organic chemistry, and the equilibrium necessary for cations and anions. Despite the calcium role in contraction, I would not discount hypomagnesemia in having a disease role because of the intracellular-extracellular connection. The description you pasted reminds me also of a lecture given a few years ago by the Nobel Laureate that year on the mechanism of cell division.